Matthew K. Szot
Equibles does not estimate personal net worth.
Get an email with a short summary when Cadrenal Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get CVKD alertsAbout Matthew K. Szot
Matthew K. Szot is recorded as CFO at Cadrenal Therapeutics, Inc. (CVKD) since January 25, 2023. Cadrenal Therapeutics, Inc. reported in an 8-K filed June 3, 2026 that Matthew K. Szot was terminated as Chief Financial Officer, effective May 28, 2026. Cadrenal Therapeutics, Inc. reported in an 8-K filed January 25, 2023 that Matthew K. Szot was appointed Chief Financial Officer. Cadrenal Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Cadrenal Therapeutics, Inc. includes John P. Sharp (CFO), Quang X. Pham (CFO, Chief Accounting Officer and Board Member), Jeffrey Cole (COO) and 7 others.
“On May 28, 2026, Cadrenal Therapeutics, Inc. (the “Company”) and Matthew K. Szot mutually agreed to his transition from the role of Chief Financial Officer, effective May 28, 2026.”
“WHEREAS, the Executive shall serve as the Company’s Chief Financial Officer commencing on the Effective Date;”
Affiliation history
-
Current
2023-01-25–present
-
2023-01-25–2026-05-28
Company network
Leadership on record at Cadrenal Therapeutics, Inc.
- John P. Sharp CFO
- Quang X. Pham CFO, Chief Accounting Officer, Board Member
- Jeffrey Cole COO
- Class I Directors Board Member
- Glynn Wilson Board Member
- John Murphy Board Member
- Lee Golden Board Member
- Lee Scott Golden, M.D. Board Member
- Robert Lisicki Board Member
- Steven Zelenkofske Board Member